Decrease of fructosamine levels during treatment with adalimumab in patients with both diabetes and rheumatoid arthritis

I C van Eijk; M J L Peters; M T Nurmohamed; A W van Deutekom; B A C Dijkmans; S Simsek

doi:https://doi.org/10.1530/EJE-06-0693

Decrease of fructosamine levels during treatment with adalimumab in patients with both diabetes and rheumatoid arthritis

I C van Eijk, M J L Peters, M T Nurmohamed, A W van Deutekom, B A C Dijkmans, S Simsek

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Tumour necrosis factor alpha (TNFalpha) is a pro-inflammatory cytokine which has been closely linked to obesity and insulin resistance. We present two cases of patients with rheumatoid arthritis (RA) and concomitant diabetes mellitus, who showed a marked decrease of fructosamine levels after initiating therapy with adalimumab, a TNFalpha-blocking agent, for active RA. This finding may implicate that TNFalpha blockade causes better glycaemic control in RA patients with concomitant diabetes, possibly by improving insulin resistance.

Original language	English
Pages (from-to)	291-3
Number of pages	3
Journal	European journal of endocrinology
Volume	156
Issue number	3
DOIs	https://doi.org/10.1530/EJE-06-0693
Publication status	Published - Mar 2007

Keywords

Adalimumab
Adult
Aged
Anti-Inflammatory Agents/adverse effects
Antibodies, Monoclonal/adverse effects
Antibodies, Monoclonal, Humanized
Arthritis, Rheumatoid/blood
Diabetes Mellitus, Type 1/blood
Diabetes Mellitus, Type 2/blood
Female
Fructosamine/blood
Humans
Male
Tumor Necrosis Factor-alpha/immunology

Access to Document

https://doi.org/10.1530/EJE-06-0693

Cite this

@article{5b84bf0caefd4759ba67536c00a416ac,

title = "Decrease of fructosamine levels during treatment with adalimumab in patients with both diabetes and rheumatoid arthritis",

abstract = "Tumour necrosis factor alpha (TNFalpha) is a pro-inflammatory cytokine which has been closely linked to obesity and insulin resistance. We present two cases of patients with rheumatoid arthritis (RA) and concomitant diabetes mellitus, who showed a marked decrease of fructosamine levels after initiating therapy with adalimumab, a TNFalpha-blocking agent, for active RA. This finding may implicate that TNFalpha blockade causes better glycaemic control in RA patients with concomitant diabetes, possibly by improving insulin resistance.",

keywords = "Adalimumab, Adult, Aged, Anti-Inflammatory Agents/adverse effects, Antibodies, Monoclonal/adverse effects, Antibodies, Monoclonal, Humanized, Arthritis, Rheumatoid/blood, Diabetes Mellitus, Type 1/blood, Diabetes Mellitus, Type 2/blood, Female, Fructosamine/blood, Humans, Male, Tumor Necrosis Factor-alpha/immunology",

author = "{van Eijk}, {I C} and Peters, {M J L} and Nurmohamed, {M T} and {van Deutekom}, {A W} and Dijkmans, {B A C} and S Simsek",

year = "2007",

month = mar,

doi = "https://doi.org/10.1530/EJE-06-0693",

language = "English",

volume = "156",

pages = "291--3",

journal = "European journal of endocrinology",

issn = "0804-4643",

publisher = "BioScientifica Ltd.",

number = "3",

}

TY - JOUR

T1 - Decrease of fructosamine levels during treatment with adalimumab in patients with both diabetes and rheumatoid arthritis

AU - van Eijk, I C

AU - Peters, M J L

AU - Nurmohamed, M T

AU - van Deutekom, A W

AU - Dijkmans, B A C

AU - Simsek, S

PY - 2007/3

Y1 - 2007/3

N2 - Tumour necrosis factor alpha (TNFalpha) is a pro-inflammatory cytokine which has been closely linked to obesity and insulin resistance. We present two cases of patients with rheumatoid arthritis (RA) and concomitant diabetes mellitus, who showed a marked decrease of fructosamine levels after initiating therapy with adalimumab, a TNFalpha-blocking agent, for active RA. This finding may implicate that TNFalpha blockade causes better glycaemic control in RA patients with concomitant diabetes, possibly by improving insulin resistance.

AB - Tumour necrosis factor alpha (TNFalpha) is a pro-inflammatory cytokine which has been closely linked to obesity and insulin resistance. We present two cases of patients with rheumatoid arthritis (RA) and concomitant diabetes mellitus, who showed a marked decrease of fructosamine levels after initiating therapy with adalimumab, a TNFalpha-blocking agent, for active RA. This finding may implicate that TNFalpha blockade causes better glycaemic control in RA patients with concomitant diabetes, possibly by improving insulin resistance.

KW - Adalimumab

KW - Adult

KW - Aged

KW - Anti-Inflammatory Agents/adverse effects

KW - Antibodies, Monoclonal/adverse effects

KW - Antibodies, Monoclonal, Humanized

KW - Arthritis, Rheumatoid/blood

KW - Diabetes Mellitus, Type 1/blood

KW - Diabetes Mellitus, Type 2/blood

KW - Female

KW - Fructosamine/blood

KW - Humans

KW - Male

KW - Tumor Necrosis Factor-alpha/immunology

U2 - https://doi.org/10.1530/EJE-06-0693

DO - https://doi.org/10.1530/EJE-06-0693

M3 - Article

C2 - 17322487

SN - 0804-4643

VL - 156

SP - 291

EP - 293

JO - European journal of endocrinology

JF - European journal of endocrinology

IS - 3

ER -